💊 Препараты А-Я 🧬 Мишени 🛠 Инструменты 📚 Руководства
Все препараты Классы препаратов Терапевтические области Побочные Эффекты
Руководства Глоссарий Хронология
Сравнения Путешествия препаратов Группы лекарственных средств
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Tocainide

CHEMBL1762 Phase 4 Одобрено Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
192.3 g/mol
LogP
0.8
Phase
4

Tocainide is a class Ib antiarrhythmic agent structurally related to lidocaine that blocks cardiac sodium channels in an activated/inactivated state-dependent manner, reducing the rate of rise of the action potential and shortening the effective refractory period in ventricular myocardium. It was used orally for life-threatening ventricular arrhythmias but was withdrawn from clinical use due to severe adverse effects including agranulocytosis, pulmonary fibrosis, and pulmonary edema. Unlike lidocaine, it is orally bioavailable due to its primary amine structure, but this did not outweigh its toxicity profile.

Молекулярная масса

192,2600 g/mol

LogP

0,80

TPSA

55,10 Ų

Правило пяти Липинского

Соответствует

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Структура

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1cccc(C)c1NC(=O)C(C)N

                

                

                
                

                    
InChI

                    
InChI=1S/C11H16N2O/c1-7-5-4-6-8(2)10(7)13-11(14)9(3)12/h4-6,9H,12H2,1-3H3,(H,13,14)

                

                

                

                    
                    

                        
Molecular Formula

                        
C11H16N2O

                    

                    
                    

                        
HBD / HBA

                        
2 / 2

                    

                    
                    

                        
Вращаемые Связи

                        
2

                    

                    
                    
                    

                        
Тяжёлые Атомы

                        
14

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Часто задаваемые вопросы

                

                    
                    

                        
                        

                            
Tocainide is a class Ib antiarrhythmic agent structurally related to lidocaine that blocks cardiac sodium channels in an activated/inactivated state-dependent manner, reducing the rate of rise of the action potential and shortening the effective refractory period in ventricular myocardium. It was used orally for life-threatening ventricular arrhythmias but was withdrawn from clinical use due to severe adverse effects including agranulocytosis, pulmonary fibrosis, and pulmonary edema. Unlike lidocaine, it is orally bioavailable due to its primary amine structure, but this did …

                        

                    

                    

                    

                    

                    

                    

                        
                        

                            
Yes, Tocainide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1762.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 38945.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
Медицинский отказ от ответственности

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.